Regulation of Lipocalin-2 oncogene and its impact on gene polymorphisms on breast cancer patients in Jeddah, Saudi Arabia

Abstract

Objectives:To identify the impact of Lipocalin-2 (LCN2) gene polymorphisms on breast cancer patients in Jeddah, Saudi Arabia.Methods:It is a case control study in which blood samples of participants from Medical Reference Clinics and King Abdulaziz University Hospital in Jeddah, Saudi Arabia have been taken between 2014 and 2016. This study recruited 128 participants (50% control, 50% patients) and used Tetra-Primer amplification-refractory mutation system-polymerase chain reaction method for the detection of missense SNP (rs11556770). The study measured LCN2 plasma protein expression by enzyme-linked immunosorbent assay technique.Results:The results have shown that 100% of the genotypes were normal allele (G/G). In contrast, the plasma level of LCN2 was considerably elevated among patients as compared to control (p=0.001), and higher in invasive ductal carcinoma patients (p=0.001). The LCN2 protein expression in plasma level was significantly elevated among patients, particularly who demonstrated invasive ductal carcinoma.Conclusion:There is no significant relationship between breast cancer patients and LCN2 gene polymorphisms (rs11556770).

Pharmacological targets of SGLT2 inhibitors on IgA nephropathy and membranous nephropathy: a mendelian randomization study

“…A study conducted among Hong Kong Chinese individuals revealed an association between the rs3814526 SNP of LCN2 and hypertension ( Ong et al, 2011 ). Conversely, research involving breast cancer patients indicated elevated levels of LCN2 protein bothin the plasma and breast cancer cells compared to controls, although no significant correlation was observed with polymorphisms in the LCN2 gene ( Linjawi et al, 2018 ). Our findings suggest a potential therapeutic mechanism whereby the SGLT2 inhibitor dapagliflozin may target the rs3099844 SNP of the LCN2 gene to inhibit LCN2 expression in the treatment of IgAN.…”

Exploring the multifaceted role of obesity in breast cancer progression

“…Furthermore, LCN2 expression was significantly higher in inflammatory BCa (IBC) tumors regardless of the molecular subtype than in non-inflammatory BCa tumors. In patients with inflammatory BCa, increased expression of LCN2 is associated with poor prognosis and a lower overall survival rate ( Linjawi et al, 2018 ). The in vivo and in vitro studies by Yan et al found that LCN2 is highly expressed in fat cells, which leads to insulin resistance.…”